Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Proteoliposome-based ZnT8 self-antigen for type 1 diabetes diagnosis

Proteoliposome-based ZnT8 self-antigen for type 1 diabetes diagnosis

US Patent 11892457 · Granted Feb 6, 2024

Estimated economic value: $54,002,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Cell-based ZNT8 assay2025
Cell-based ZNT8 assay2025
Near-infrared-II nanoparticles and related compositions and methods2025
Facile formation of highly active and stable hydrogen evolution catalysts2025
Antibodies to human ZnT82024
Antibodies to human ZnT82024
Deep learning for near-infrared fluorescence imaging enhancement2024
ZnT8 assays for drug development and pharmaceutical compositions2023
Assays, sensing platforms, and methods for diagnosis of coronavirus infection an2023
Highly sustained electrodes and electrolytes for salty alkaline and neutral wate2022
Electrolytes, current collectors, and binders for rechargeable metal-ion batteri2021
Methods and systems for diagnosis and treatment of viral infections2021